I-BET151 (GSK1210151A)

Catalog No.S2780

I-BET151 (GSK1210151A) Chemical Structure

Molecular Weight(MW): 415.44

I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 170 In stock
USD 270 In stock
USD 870 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies.

    Theranostics, 2016, 6(2):219-30.. I-BET151 (GSK1210151A) purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.
Features Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies.
Targets
BRD3 [1]
(Cell-free assay)
BRD2 [1]
(Cell-free assay)
BRD4 [1]
(Cell-free assay)
0.25 μM 0.5 μM 0.79 μM
In vitro

I-BET151 exhibits potent selectivity over an extensive range of diverse protein types such as COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, ion channels, and transporters. Similar to I-BET762 (GSK525762A), I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with KD of 0.02-0.1 μM, and significantly inhibits lipopolysaccharide-stimulated IL-6 cytokine production in human peripheral blood mononuclear cells (PBMC) and whole blood (WB) as well as rat WB with IC50 of 0.16 μM, 1.26 μM, and 1.26 μM, respectively. I-BET151 (0.5 or 5 μM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins in HL60 nuclear extract to acetylated histone peptides. I-BET151 has potent efficacy against cell lines harboring different MLL-fusions such as MV4;11, RS4;11, MOLM13, and NOMO1 cells with IC50 of 15-192 nM. Consistently, I-BET151 completely ablates the colony-forming potential of MLL-fusion-driven leukaemias (MOLM13) but not leukaemias driven by tyrosine kinase activation (K562). I-BET151 also displays potent efficacy in both liquid culture and clonogenic assays using primary murine progenitors transformed with either MLL-ENL or MLL-AF9. I-BET151 treatment significantly induces apoptosis and prominent G0/G1 arrest in MLL-fusion cell lines driven by distinct MLL fusions (MOLM13 and MV4;11 containing MLL-AF9 and MLL-AF4, respectively) but not the K562 cells, probably due to the inhibition of transcription of BCL2, C-MYC and CDK6 by blocking the recruitment of BRD3/4, PAFc and SEC components into transcriptional start site (TSS). [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4;11 NE[5OFBkgXSxdH;4bYNqfHliYYPzZZk> M3jlUJ4yODBizszN NWfSTY1ETE2VTx?= M{HoUWlEPTB;Mk[gcm0> Moe4NlE6PjR|NEC=
RS4;11 NV\Ub206[3m2b4TvfIlkcXS7IHHzd4F6 NW\iV3E2hjFyMDFOwG0> NXrvR4tUTE2VTx?= NIjW[HVKSzVyPUG5NkBvVQ>? NEHpXlkzOTl4NEO0NC=>
MOLM13 M4j5V4N6fG:2b4jpZ4l1gSCjc4PhfS=> M2LRcJ4yODBizszN MnSxSG1UVw>? MlvzTWM2OD1zMkCgcm0> MV2yNVk3PDN2MB?=
NOMO1 M4nYXoN6fG:2b4jpZ4l1gSCjc4PhfS=> M3L5bJ4yODBizszN M37ERmROW09? M4LxdGlEPTB;MUWgcm0> NInoUXYzOTl4NEO0NC=>
HEL NW\zTZJp[3m2b4TvfIlkcXS7IHHzd4F6 M2X1Rp4yODBizszN NYXne|lUTE2VTx?= MXLJR|UxRTFizszN NWXYRXZUOjF7NkSzOFA>
K562 MUDjfZRwfG:6aXPpeJkh[XO|YYm= MmHVglExOCEQvF2= NV\VeoJ7TE2VTx?= M4Pte2lEPTB-MUCwJO69VQ>? NHnodGYzOTl4NEO0NC=>
MEG01 Moj3Z5l1d3SxeHnjbZR6KGG|c3H5 M4PZZp4yODBizszN M1vaPGROW09? MWrJR|UxRTJ3IN88US=> MmTTNlE6PjR|NEC=
HL60 M1rIcIN6fG:2b4jpZ4l1gSCjc4PhfS=> M374fJ4yODBizszN M1SxSGROW09? NIPSUJJKSzVyPUi5NEBvVQ>? M{DJUlIyQTZ2M{Sw
MV4;11 NXjZflh[SXCxcITvd4l{KGG|c3H5 MV\+NVAxKM7:TR?= M3TnWGROW09? MkHQbY5lfWOnczDhdI9xfG:|aYO= MWSyNVk3PDN2MB?=
MOLM13 M2nz[2Fxd3C2b4Ppd{Bie3OjeR?= NWHMdYVShjFyMDFOwG0> NFPvc|dFVVOR NGfaWXhqdmS3Y3XzJIFxd3C2b4Ppdy=> NGToUFkzOTl4NEO0NC=>
MV4;11 M4fETGZ2dmO2aX;uJIF{e2G7 MUXEUXNQ NWXBVpRk\GWlcnXhd4V{KHSqZTDy[YNzfWm2bXXueEBw\iCEUlSzM|Qh[W6mIHntdIFqemWmIILlZ5J2cXSvZX70JI9nKEOGS{mgZY5lKFCDRkGgeI8hfGinIITyZY5{[3KrcITpc45idCC|dHHyeEB{cXSn MUOyNVk3PDN2MB?=
PBMC M{\XWmZ2dmO2aX;uJIF{e2G7 NHPHS2xFVVOR MYXpcohq[mm2czDJUE03KHerdHigdGlEPTBib3[gOk44 MmHTNlI1OzdzMUW=
A2 NH;kd5BHfW6ldHnvckBie3OjeR?= NWTCNGhjhjFyIN88US=> NWPQW5h1TE2VTx?= MmPRdoVi[3SrdnH0[ZMhdGG2ZX70JGhKXi1z MnnsNlMzPTV{MUi=
A72 Mn3rSpVv[3Srb36gZZN{[Xl? NXfEZ|VjhjFyIN88US=> NUnhcYpJTE2VTx?= Mnm4doVi[3SrdnH0[ZMhdGG2ZX70JGhKXi1z MlnmNlMzPTV{MUi=
BC1 NUG4dpI5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWH+NUDPxE1? NYL1TWN{TE2VTx?= NVflRnVNUUN3ME2yNlAhdk1? MlnyNlM4QTJ2NEi=
BC3 NFrBSJdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NIry[4N,OSEQvF2= NInuTVBFVVOR M1X0bWlEPTB;NE[wJI5O NHS1dFYzOzd7MkS0PC=>
BCBL1 M{i2W2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkHKglEh|ryP NGrTSopFVVOR NVv3cW42UUN3ME2zN|Ahdk1? MYKyN|c6OjR2OB?=
BJAB NI[5dIVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MkLuglEh|ryP MnzFSG1UVw>? NUj3VFRrUUN3ME25O|Ahdk1? NGDY[mszOzd7MkS0PC=>
Namalwa M2fSdGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NV\DNXk4hjFizszN Mo\rSG1UVw>? MkXITWM2OD17N{Cgcm0> MXSyN|c6OjR2OB?=
Jurkat NX3nNotzT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4fOV54yKM7:TR?= MlTqSG1UVw>? MV\JR|UxRTF{MkCgcm0> NYW4RZZVOjN5OUK0OFg>
MM1S MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUT+NUDPxE1? MmLrSG1UVw>? MkTQTWM2OD15NkCgcm0> M3LjdVI{Pzl{NES4
U266 MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3vSbZ4yKM7:TR?= MlHxSG1UVw>? M1rDPWlEPTB;OUWwJI5O NYDIdZFNOjN5OUK0OFg>
UM-PEL-1 NGL1dnlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NI[4Spd,OSEQvF2= NUTQU|E6TE2VTx?= MoDVTWM2OD1{MUCgcm0> M4HM[|I{Pzl{NES4
UM-PEL-3 MmH1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlTFglEh|ryP MnmySG1UVw>? M1H5SGlEPTB;MUiwJI5O NIDL[VMzOzd7MkS0PC=>
BC1 M2XUOmZ2dmO2aX;uJIF{e2G7 NGjRVZM2ODBibl2= M1H3TmROW09? M3LFRolv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= Mn65NlM4QTJ2NEi=
BC3 MnvISpVv[3Srb36gZZN{[Xl? Mn3YOVAxKG6P M1fWd2ROW09? MmjpbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dB?= NIr2No8zOzd7MkS0PC=>
BC1 MoXoSpVv[3Srb36gZZN{[Xl? NF;Hb5M5ODBibl2= M4DjT2ROW09? MVry[YR2[2W|IHOtUZlkKHC{b4TlbY4hdGW4ZXzz MUWyN|c6OjR2OB?=
BC3 NXv5NYhZTnWwY4Tpc44h[XO|YYm= NVPqO2pMQDByIH7N NIXiUo1FVVOR MkH6doVlfWOnczDjMW16[yCycn;0[YlvKGyndnXsdy=> MX[yN|c6OjR2OB?=
H929 NGnH[mNHfW6ldHnvckBie3OjeR?= M2TBW54yKM7:TR?= M1TFcGROW09? M4G5dIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MUWyOFM{PTR7OR?=
KMS12PE MWTGeY5kfGmxbjDhd5NigQ>? MUT+NUDPxE1? NXfWPYRZTE2VTx?= MU\pcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 MmC2NlQ{OzV2OUm=
KMS12BM M3PteWZ2dmO2aX;uJIF{e2G7 MmfqglEh|ryP NVXPOYRrTE2VTx?= NGq0cZRqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NETSbGgzPDN|NUS5PS=>
KMS18 NEP5TWdHfW6ldHnvckBie3OjeR?= MnrVglEh|ryP NEHnOXJFVVOR MnHBbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= Ml;ONlQ{OzV2OUm=
KMS11 NVe0WIM3TnWwY4Tpc44h[XO|YYm= NXLzSIF3hjFizszN MX;EUXNQ NX7LNXp4cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MUOyOFM{PTR7OR?=
RPMI8226 M4TOfmZ2dmO2aX;uJIF{e2G7 MkXKglEh|ryP M1PM[WROW09? MknjbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NF7zfZkzPDN|NUS5PS=>
H929 NXjYcJhwSXCxcITvd4l{KGG|c3H5 MnzxglEh|ryP MWDEUXNQ M{XSTolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NUHRVId4OjR|M{W0PVk>
KMS12PE NHvuS4dCeG:ydH;zbZMh[XO|YYm= NFzyZlR,OSEQvF2= MVvEUXNQ NWTxWYc4cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NV\WeI9GOjR|M{W0PVk>
KMS12BM MmrhRZBweHSxc3nzJIF{e2G7 NVP0OmFlhjFizszN MnPDSG1UVw>? NHLGeXhqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NHvFTIMzPDN|NUS5PS=>
KMS18 Mn7WRZBweHSxc3nzJIF{e2G7 MYT+NUDPxE1? MWrEUXNQ NV;G[ZhncW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MUKyOFM{PTR7OR?=
KMS11 NYPIfY9RSXCxcITvd4l{KGG|c3H5 NVnuV2Y6hjFizszN MYHEUXNQ MkCzbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NF7FWmkzPDN|NUS5PS=>
RPMI8226 MYXBdI9xfG:|aYOgZZN{[Xl? MmjDglEh|ryP MkKwSG1UVw>? MnHibY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NXnHZW1qOjR|M{W0PVk>
U87MG NVXTZ2hVTnWwY4Tpc44h[XO|YYm= Ml36glExKM7:TR?= M4LhbmROW09? NUDDbnl5emWmdXPld{BWQDePRzDj[YxtfWyjcjDBWHAhf2m2aDDJR|UxKG:oIEGuNFUh|ryP M{HFRlI1PDl4M{ix
A172 MWfGeY5kfGmxbjDhd5NigQ>? MX;+NVAh|ryP NXe2XFBsTE2VTx?= M1uyb5Jm\HWlZYOgZ4VtdHWuYYKgRXRRKHerdHigTWM2OCCxZjCxMlI5KM7:TR?= NWLvUpBWOjR2OU[zPFE>
SW1783 MlK5SpVv[3Srb36gZZN{[Xl? M4nBRZ4yOCEQvF2= NXnVZXlnTE2VTx?= NWXOOppmemWmdXPld{Bk\WyudXzhdkBCXFBid3n0bEBKSzVyIH;mJFIvPjhizszN MWqyOFQ6PjN6MR?=
U87MG MV\GeY5kfGmxbjDhd5NigQ>? MVz+NVAh|ryP NEXJXm1FVVOR M4nReIlv[3KnYYPld{Bxem:yb4L0bY9vKG:oIHPlcIx{KGmwIITo[UBIOS:VIITyZY5{cXSrb36= M2fvXlI1PDl4M{ix
RAW267.4 M4HDSWZ2dmO2aX;uJIF{e2G7 MkjZNUDPxE1? NHLBSHdFVVOR MonHdoVlfWOnczDJUE03KHC{b3T1Z5Rqd25iaX7keYNm\CCkeTDMVHM> M4foelI1QDV7MEC4
RAW267.4 MVzGeY5kfGmxbjDhd5NigQ>? MWixJO69VQ>? MWTEUXNQ NECxV3Fz\WS3Y3XzJJRp\SCjc4PvZ4lifGmxbjDi[ZR4\WWwIFLSSFQh[W6mIHHj[ZR6dGG2ZXSgdFY2 MUmyOFg2QTByOB?=
Me007 MnrCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlXyglExOCEQvF2= MXPEUXNQ Mmi1bY5pcWKrdIOgeIhmKGe{b4f0bC=> MVKyOFkxPjF|Nx?=
SK-Mel-28 MljDS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXL+NVAxKM7:TR?= MXfEUXNQ NY\6V|lrcW6qaXLpeJMhfGinIHfyc5d1cA>? NWrze3RxOjR7ME[xN|c>
Mel-RMU NEfnbYlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MX7+NVAxKM7:TR?= M{XkfWROW09? NXHUNGNjcW6qaXLpeJMhfGinIHfyc5d1cA>? NYO5PXlWOjR7ME[xN|c>
Mel-JD M{HaXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mom2glExOCEQvF2= NWTteFJHTE2VTx?= NFHJUW9qdmirYnn0d{B1cGViZ4Lve5Rp MnTwNlQ6ODZzM{e=
Mel-RM NFLQOYVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NInjWXd,OTByIN88US=> MUXEUXNQ NHHsUHFqdmirYnn0d{B1cGViZ4Lve5Rp M4C4SFI1QTB4MUO3
Me007 MYDBdI9xfG:|aYOgZZN{[Xl? NUf3cZNFhjFyMDFOwG0> MVzEUXNQ NU\PfnQ2cW6mdXPld{BieG:ydH;zbZM> Mmf4NlQ6ODZzM{e=
SK-Mel-28 NGfZRVdCeG:ydH;zbZMh[XO|YYm= MlzBglExOCEQvF2= NHOwdnFFVVOR MXrpcoR2[2W|IHHwc5B1d3Orcx?= NWfrOFR4OjR7ME[xN|c>
Mel-RMU MVTBdI9xfG:|aYOgZZN{[Xl? NYi4TFNFhjFyMDFOwG0> NUjIe5hrTE2VTx?= M3rvOYlv\HWlZYOgZZBweHSxc3nz MkL2NlQ6ODZzM{e=
Mel-JD NEPM[|JCeG:ydH;zbZMh[XO|YYm= NID2XId,OTByIN88US=> NIDzdWRFVVOR MojmbY5lfWOnczDhdI9xfG:|aYO= NWfm[XZkOjR7ME[xN|c>
Mel-RM M{fBW2Fxd3C2b4Ppd{Bie3OjeR?= NYfTU3V5hjFyMDFOwG0> NYj2SpBpTE2VTx?= NUPaTndDcW6mdXPld{BieG:ydH;zbZM> MlPaNlQ6ODZzM{e=
Me007 M1XEbGZ2dmO2aX;uJIF{e2G7 MX2xNEDPxE1? M4T5WGROW09? M3jJd4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? MXSyOFkxPjF|Nx?=
SK-Mel-28 Ml;PSpVv[3Srb36gZZN{[Xl? NEW2cZkyOCEQvF2= NFnMSXhFVVOR M3XzWIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? MXqyOFkxPjF|Nx?=
Mel-RMU MmXSSpVv[3Srb36gZZN{[Xl? M4DXV|ExKM7:TR?= MV;EUXNQ Mn3DbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy MVeyOFkxPjF|Nx?=
Mel-JD MoS5SpVv[3Srb36gZZN{[Xl? MVixNEDPxE1? NGLWTWFFVVOR NEXYOWtqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIJ6KHWycnXneYxifGmxbjDv[kBxOjF? NWjVeJRbOjR7ME[xN|c>
Mel-RM NFv0WodHfW6ldHnvckBie3OjeR?= M3n1ZlExKM7:TR?= M{XjZ2ROW09? Mn;5bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy MkWwNlQ6ODZzM{e=
Me007 M1nVRmZ2dmO2aX;uJIF{e2G7 M2DyblExKM7:TR?= M2DCc2ROW09? MkTleZBz\We3bHH0[ZMheHKxYYDvdJRwfGmlIHHu[EBk\WyuIHP5Z4xmKGG{cnXzeEBo\W6ncx?= NIfFVGozPDlyNkGzOy=>
SK-Mel-28 MoLESpVv[3Srb36gZZN{[Xl? MWSxNEDPxE1? MWHEUXNQ MV;1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| MUKyOFkxPjF|Nx?=
Mel-RMU M{XJZ2Z2dmO2aX;uJIF{e2G7 M3XUPVExKM7:TR?= M4XZVWROW09? MXX1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| NHy1TVUzPDlyNkGzOy=>
Mel-JD NUnKXnJITnWwY4Tpc44h[XO|YYm= M4rpO|ExKM7:TR?= NF7ET2NFVVOR NHK3ZWN2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz MXKyOFkxPjF|Nx?=
Mel-RM M{HiNmZ2dmO2aX;uJIF{e2G7 NH36coEyOCEQvF2= M1PycmROW09? NUHsZW1CfXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> MlW4NlQ6ODZzM{e=

... Click to View More Cell Line Experimental Data

In vivo Administration of I-BET151 at 30 mg/kg/day significantly inhibits tumor growth of murine MLL-AF9 and human MLL-AF4 leukaemia in mice, and provides marked survival benefit. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence anisotropy (FP) ligand displacement assay:

All components are dissolved in buffer of composition 50 mM HEPES pH 7.4, 150 mM NaCl and 0.5 mM CHAPS with final concentrations of BRD 2/3/4 75 nM, fluorescent ligand 5 nM. 10 μL of this reaction mixture is added using a micro multidrop to wells containing 100 nL of various concentrations of I-BET151 or DMSO vehicle (1% final) in Greiner 384 well Black low volume microtitre plate and equilibrated in the dark for 60 minutes at room temperature. Fluorescence anisotropy is read in Envision (lex = 485 nm, lEM = 530 nm; Dichroic = 505 nM).
Cell Research:

[1]

+ Expand
  • Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 24, or 72 hours
  • Method:

    Cells are exposed to various concentrations of I-BET151 for 24 or 72 hours in 384-well or 96-well plates. For cell growth inhibition assays, plates are added with CellTiter-Glo reagent using a volume equivalent to the cell culture volume in the wells, shaken for approximately 2 minutes and chemiluminescent signal is read on the Analyst GT or EnVision Plate Reader. For cell proliferation assays, CellTiter-Aqueous One is added to each well and plates are incubated for 4 hours at 37 °C. Absorbance is read at 490 nm on a SpectraMax Gemini reader


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: NOD-SCID mice injected intravenously with MV4;11 cells, and C57BL/6 mice injected intravenously with MLL-AF9 cells
  • Formulation: Dissolved in normal saline containing 5% (v/v) DMSO and 10% (w/v) Kleptose HPB
  • Dosages: ~30 mg/kg/day
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 27 mg/mL (64.99 mM)
DMSO <1 mg/mL
Water <1 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 415.44
Formula

C23H21N5O3

CAS No. 1300031-49-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) supplier | purchase I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) cost | I-BET151 (GSK1210151A) manufacturer | order I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID